Bond News

KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children

Kedrion maintains its revenues and outperformed management’s expectations.

Not for release, publication or distribution, directly or indirectly, in the United States of America (or for the account or benefit of “U.S. persons” as defined in Regulation S under the U.S. Securities Act of 1933), Canada, Australia or Japan or in any other jurisdiction where to do so would be unlawful. PRESS RELEASE –